The RMGP Biopharma Investment Fund represents an opportunity to invest alongside industry leaders in innovative early-stage biotherapeutics through a dedicated platform.

RMGP and its partners identified innovative early-stage biopharmaceutical assets as a highly attractive investment opportunity.

The fund invests in early-stage biopharmaceutical solutions alongside industry leaders such as OrbiMed, J&J, and Takeda.

The fund is dedicated to FutuRx's portfolio of first-in-class and best-in-class assets, and it invests exclusively in companies operating in Israel's FutuRx incubator.

Based on RM Global's core investment banking capabilities, the fund will provide its portfolio companies with strategic and business development support to maximize potential return.